Rare disease launch insights report
Planning to launch a rare disease therapy in Europe?
Start here.
Our Rare Disease Launch Insights Report brings together insights from more than 30 years of Sciensus experience helping biopharma companies navigate the challenges of launching rare and orphan therapies across Europe.
Discover how to:
- Navigate Europe’s complex regulatory and reimbursement landscape
- Use Early Access Programmes as a bridge to payer and patient engagement
- Manage the operational and supply chain demands unique to rare therapies
- Leverage real-world data to demonstrate value and support HTA submissions
- Strengthen adherence and patient outcomes through effective PSPs
Download your free copy and learn how to bring your rare therapy to European patients faster.
About Sciensus
Sciensus is a European leader in integrated end-to-end commercial services, supporting patients, health systems, providers and Biopharma companies. We offer distribution services, clinical care, digital solutions and patient insights to accelerate access to medicines and maximise product launches from clinical to full commercialisation. With over 30 years’ experience navigating the complex European healthcare ecosystem, Sciensus helps bring the right medicine to the right patients – faster.